Program
fludarabine
Also written as “Fludarabine”, “Cyclophosphamide,Fludarabine” and “TC-D101 CAR-T”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Multiple Myeloma · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Non-Hodgkin · Glioblastoma, led by 18 companies.
Drug pageFludarabine: every studyMany companies study it; this page follows only the 35 they lead. All 745 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Biotechits history only | 99 open or running | phase 2since Apr 5, 2026 | Mar 14, 2026 | Feb 18, 2027phase 1 · NCT07480941 |
| Hoffmann-La Rocheits history only | 60 open or running | phase 4since Jan 4, 2011 | Oct 16, 2007 | none ahead |
| Allogene Therapeuticsits history only | 32 open or running | phase 2since Dec 8, 2022 | Dec 8, 2022 | Dec 2027phase 2 · NCT06500273 |
| Hangzhou Huasai Biomedicineits history only | 22 open or running | phase 1since Jul 22, 2025 | Jul 22, 2025 | Aug 30, 2027phase 1 · NCT07105176 |
| Shanghai First Song Biotechnologyits history only | 21 open or running | early phase 1since Jul 30, 2024 | Jul 30, 2024 | none ahead |
| Adicet Therapeuticsits history only | 10 open or running | phase 1since Jan 26, 2021 | Jan 26, 2021 | none ahead |
| Biotech Equity Partners Ptyits history only | 10 open or running | phase 1since Feb 20, 2008 | Feb 20, 2008 | none ahead |
| Bristol-Myers Squibbits history only | 11 open or running | phase 1since Feb 7, 2025 | Feb 7, 2025 | Mar 15, 2029phase 1 · NCT07115745 |
| Caribou Biosciencesits history only | 11 open or running | phase 1since Nov 16, 2020 | Nov 16, 2020 | none ahead |
| CARsgen Therapeuticsits history only | 10 open or running | phase 1since Aug 9, 2016 | Aug 9, 2016 | none ahead |
| Gilead Sciences | 10 open or running | phase 1since Oct 13, 2017 | Oct 13, 2017 | none ahead |
| Johnson & Johnsonits history only | 11 open or running | phase 2since Aug 25, 2025 | Aug 25, 2025 | Apr 12, 2028phase 2 · NCT07149857 |
| Neukio Biotherapeutics (Shanghai)its history only | 11 open or running | early phase 1since Aug 19, 2025 | Aug 19, 2025 | Jan 14, 2027early phase 1 · NCT07144462 |
| Precision BioSciencesits history only | 10 open or running | phase 2since Jul 19, 2019 | Jul 19, 2019 | none ahead |
| Seah Lim M.D.its history only | 10 open or running | phase 2since Aug 29, 2012 | Aug 29, 2012 | none ahead |
| Shanghai Ming Ju Biotechnologyits history only | 11 open or running | phase 1since Feb 5, 2023 | Feb 5, 2023 | none ahead |
| Shanghai Unicar-Therapy Bio-medicine Technologyits history only | 11 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| TCRCure Biopharmaits history only | 11 open or running | early phase 1since Nov 17, 2025 | Nov 17, 2025 | Nov 30, 2027early phase 1 · NCT07246304 |
Also a collaborator on its studies: Natera.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Gilead Sciences only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 13, 2017First study: phase 1 study in Multiple MyelomaFirst studyNCT03318861 · 17 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Gilead Sciences leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03318861Multiple Myeloma · United States | 1 | Terminated | Dec 17, 2018 | 17 |
How it is read
Names in the registry
- “Fludarabine”, 40 entries
- “Cyclophosphamide,Fludarabine”, 4 entries
- “TC-D101 CAR-T”, 1 entry
- “CD19-targeted Chimeric Antigen Receptor (CAR) T Cells”, 1 entry
- “fludarabine, rituximab, pixantrone”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 7 studies
- Multiple Myeloma, 4 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 3 studies
- Lymphoma, Non-Hodgkin, 3 studies
- Glioblastoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.